ResApp (RAP AU): Low-End Pfizer Offer As Cough Trial Fails

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/narhex-life-sciences-ltd" target="_blank" data-smartkarma-citation="entities:9728:1" rel="noopener">ResApp Health (RAP AU)</a> has entered into an amended and restated Scheme Implementation Deed concerning a proposed takeover by <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US)</a>. </li>
<li>After a sensitivity/specificity cough trial fell short of a March pilot study, Pfizer Offered A$0.146/share on the 21 June. Shares have traded wide to terms since on possible retail pushback.</li>
<li>
The revised consideration of $0.208/share matches the preferred value and within the assessed value range of $0.146 - $0.279/share determined by the Independent Expert's Report on 14 July 2022.</li>
</ul>



ResApp Health (RAP AU) has entered into an amended and restated Scheme Implementation Deed concerning a proposed takeover by Pfizer Inc (PFE US). 
After a sensitivity/specificity cough trial fell short of a March pilot study, Pfizer Offered A$0.146/share on the 21 June. Shares have traded wide to terms since on possible retail pushback.

The revised consideration of $0.208/share matches the preferred value and within the assessed value range of $0.146 - $0.279/share determined by the Independent Expert's Report on 14 July 2022.


Resapp Health

ResApp (RAP AU): Pfizer Bumps Offer